Berlin \u2014 INKEF Capi\u00adtal led the consor\u00adtium of inves\u00adtors in the \u20ac64 million Series B finan\u00adcing round invest\u00adment in Hano\u00adver-based Cardior Phar\u00admaceu\u00adti\u00adcals. \u2014 In addi\u00adtion to lead inves\u00adtor INKEF, new inves\u00adtors Fund+, Sunstone, Hadean Ventures and Copa\u00adrion parti\u00adci\u00adpa\u00adted in the round. In addi\u00adtion, exis\u00adting inves\u00adtors such as LSP, BioMed\u00adPart\u00adners, Bris\u00adtol Myers Squibb and High-Tech Gr\u00fcn\u00adder\u00adfonds also parti\u00adci\u00adpa\u00adted in the finan\u00adcing round. In connec\u00adtion with the finan\u00adcing, repre\u00adsen\u00adta\u00adti\u00adves from INKEF, Fund+ and Sunstone will join the company\u2019s advi\u00adsory board.<\/p>\n
Cardior Phar\u00admaceu\u00adti\u00adcals is a leading biophar\u00admaceu\u00adti\u00adcal company pionee\u00adring the disco\u00advery and deve\u00adlo\u00adp\u00adment of RNA-based thera\u00adpeu\u00adtics to prevent, treat and reverse heart dise\u00adase. The company\u2019s mission is to provide pati\u00adents with novel thera\u00adpeu\u00adtics and diagno\u00adstics that will have a lasting impact on the treat\u00adment of heart dise\u00adase worldwide.<\/p>\n
\u201cWe believe ncRNAs can funda\u00admen\u00adtally change the treat\u00adment of heart dise\u00adase by preven\u00adting, repai\u00adring and rever\u00adsing damage to cardiac tissue. We thank our new and exis\u00adting inves\u00adtors for their support and their confi\u00addence in our ability to achieve our goal,\u201d said Dr. Clau\u00addia Ulbrich (photo), Chief Execu\u00adtive Offi\u00adcer and Co-Foun\u00adder of Cardior.<\/strong><\/p>\n INKEF Capi\u00adtal is an Amster\u00addam-based invest\u00adment fund with a port\u00adfo\u00adlio of more than 45 compa\u00adnies in the health\u00adcare and tech\u00adno\u00adlogy sectors.<\/p>\n Advi\u00adsor INKEF + Inves\u00adtor Consor\u00adtium: YPOG<\/strong> The law firm KNPZ<\/strong> (Dr. Kai Plath, Matthias Struck and Jan Sch\u00e4\u00adfer) advi\u00adsed on the tran\u00adsac\u00adtion along\u00adside the YPOG team in the IP area.<\/p>\n About YPOG<\/strong><\/p>\n YPOG is a specia\u00adlist tax and commer\u00adcial law firm, opera\u00adting in the core areas of corpo\u00adrate, funds, liti\u00adga\u00adtion, tax, tran\u00adsac\u00adtions, IT\/IP and nota\u00adrial services. The YPOG team advi\u00adses a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. Since its foun\u00adda\u00adtion in 2017, the firm has become one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. The firm and its part\u00adners are natio\u00adnally and inter\u00adna\u00adtio\u00adnally ranked by JUVE, Best Lawy\u00aders, Legal 500, Focus, and Cham\u00adbers and Part\u00adners. Today, YPOG employs more than 70 expe\u00adri\u00aden\u00adced lawy\u00aders, tax advi\u00adsors, tax specia\u00adlists and a notary in three offices in Berlin, Hamburg and Colo\u00adgne. www.ypog.law<\/p>\n","protected":false},"excerpt":{"rendered":" Berlin \u2014 INKEF Capi\u00adtal led the consor\u00adtium of inves\u00adtors in the \u20ac64 million Series B finan\u00adcing round invest\u00adment in Hano\u00ad\u00adver-based Cardior Phar\u00admaceu\u00adti\u00adcals. \u2014 In addi\u00adtion to lead inves\u00adtor INKEF, new inves\u00adtors Fund+, Sunstone, Hadean Ventures and Copa\u00adrion parti\u00adci\u00adpa\u00adted in the round. In addi\u00adtion, exis\u00adting inves\u00adtors such as LSP, BioMed\u00adPart\u00adners, Bris\u00adtol Myers Squibb and High-Tech Gr\u00fcnderfonds [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37963,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1372,1373],"tags":[],"class_list":["post-40275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-consultant","category-venture-capital-en"],"yoast_head":"\n
\nDr. Martin Scha\u00adper (Lead Part\u00adner), Partner
\nDr. Malte Berg\u00admann, Partner
\nDr. Martyna Sabat, Senior Associate
\nDr. Ansgar Frank, Asso\u00adcia\u00adted Partner
\nAnn-Kris\u00adtin Loch\u00admann, Senior Associate
\nPia Meven, Associate
\nJonas Huth, Associate
\nLukas Schmitt, Associate<\/p>\n